JP2020534361A - 置換ヌクレオシド、ヌクレオチド、及びそのアナログ - Google Patents

置換ヌクレオシド、ヌクレオチド、及びそのアナログ Download PDF

Info

Publication number
JP2020534361A
JP2020534361A JP2020537296A JP2020537296A JP2020534361A JP 2020534361 A JP2020534361 A JP 2020534361A JP 2020537296 A JP2020537296 A JP 2020537296A JP 2020537296 A JP2020537296 A JP 2020537296A JP 2020534361 A JP2020534361 A JP 2020534361A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
alkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020537296A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534361A5 (https=
Inventor
ベイグルマン・レオニード
デヴァル・ジェローム
プラビク・マリヤ
Original Assignee
ヤンセン・バイオファーマ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン・バイオファーマ・インコーポレイテッド filed Critical ヤンセン・バイオファーマ・インコーポレイテッド
Publication of JP2020534361A publication Critical patent/JP2020534361A/ja
Publication of JP2020534361A5 publication Critical patent/JP2020534361A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2020537296A 2017-09-18 2018-09-18 置換ヌクレオシド、ヌクレオチド、及びそのアナログ Pending JP2020534361A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762560110P 2017-09-18 2017-09-18
US62/560,110 2017-09-18
PCT/IB2018/057188 WO2019053696A1 (en) 2017-09-18 2018-09-18 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

Publications (2)

Publication Number Publication Date
JP2020534361A true JP2020534361A (ja) 2020-11-26
JP2020534361A5 JP2020534361A5 (https=) 2021-10-28

Family

ID=63794555

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020537296A Pending JP2020534361A (ja) 2017-09-18 2018-09-18 置換ヌクレオシド、ヌクレオチド、及びそのアナログ

Country Status (17)

Country Link
US (2) US11149049B2 (https=)
EP (1) EP3684782A1 (https=)
JP (1) JP2020534361A (https=)
KR (1) KR102696517B1 (https=)
CN (1) CN111542531B (https=)
AU (1) AU2018332540B2 (https=)
CA (1) CA3075950A1 (https=)
CL (1) CL2020000685A1 (https=)
CR (1) CR20200126A (https=)
EA (1) EA202090775A1 (https=)
EC (1) ECSP20022130A (https=)
IL (1) IL273341A (https=)
MA (1) MA50172A (https=)
MX (1) MX2020002925A (https=)
PH (1) PH12020550114A1 (https=)
SG (1) SG11202002295QA (https=)
WO (1) WO2019053696A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023022216A1 (ja) * 2021-08-20 2023-02-23 塩野義製薬株式会社 ウイルス増殖抑制作用を有するヌクレオシド誘導体及びそれらのプロドラッグ
KR20230127294A (ko) * 2020-12-30 2023-08-31 서던 유니버시티 오브 사이언스 앤드 테크놀로지 코로나 바이러스 감염을 치료하기 위한 방법 및 변형된뉴클레오사이드
JP2023540225A (ja) * 2020-08-27 2023-09-22 ギリアード サイエンシーズ， インコーポレイテッド ウイルス感染症の治療のための化合物及び方法
JP2023541960A (ja) * 2020-09-17 2023-10-04 メレティオス セラピューティクス ウイルス感染を治療するための化合物
KR20230170745A (ko) * 2021-04-16 2023-12-19 길리애드 사이언시즈, 인코포레이티드 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014209983A1 (en) 2013-06-26 2014-12-31 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
TN2016000566A1 (en) 2014-06-24 2018-04-04 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
AU2018262501B2 (en) 2017-05-01 2020-12-10 Gilead Sciences, Inc. Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
CR20200126A (es) * 2017-09-18 2020-07-11 Janssen Biopharma Inc Nucleósidos sustituidos, nucleótidos y análogos de estos
EP3946611A2 (en) 2019-03-31 2022-02-09 Yeda Research and Development Co. Ltd Anti-viral and anti-tumoral compounds
CN110724174B (zh) * 2019-09-10 2021-02-05 广州六顺生物科技股份有限公司 吡咯并三嗪类化合物、组合物及其应用
CN110776512A (zh) * 2019-11-28 2020-02-11 成都傲飞生物化学品有限责任公司 一种核苷类似物的制备方法
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
AU2021224588B2 (en) * 2020-02-18 2024-07-18 Gilead Sciences, Inc. Antiviral compounds
TWI775313B (zh) * 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
CN113292565B (zh) * 2020-02-24 2023-01-31 浙江森科建设有限公司 核苷类化合物及其制备方法和应用
CN113387954B (zh) * 2020-03-11 2024-03-19 上海特化医药科技有限公司 一种瑞德西韦中间体的制备方法
JP7554841B2 (ja) 2020-03-12 2024-09-20 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノヌクレオシドを調製する方法
WO2021207049A1 (en) 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CN112778310B (zh) 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN111961057A (zh) * 2020-05-26 2020-11-20 李小冬 一种α构型核苷及其在治疗猫冠状病毒感染的应用
CA3179226A1 (en) 2020-05-29 2021-12-02 Tomas Cihlar Remdesivir treatment methods
AU2021296841B2 (en) * 2020-06-24 2025-01-23 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
CN111793101B (zh) * 2020-07-17 2022-09-30 四川大学 C-核苷化合物的合成方法
MX2023001002A (es) 2020-07-24 2023-03-01 Univ California Farmacos antivirales, composiciones farmaceuticas, y metodos.
WO2022038539A2 (en) * 2020-08-18 2022-02-24 Yeda Research And Development Co. Ltd. Anti-viral and anti-tumoral compounds
AU2021330835B2 (en) 2020-08-24 2023-12-14 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
CN112142810A (zh) * 2020-09-29 2020-12-29 佛山科学技术学院 核苷酸双氨基磷酸酯化合物、其药物组合物及其制备方法和应用
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
CN112300236A (zh) * 2020-10-21 2021-02-02 佛山科学技术学院 核苷酸混合氨基磷酸酯化合物、其药物组合物及其应用
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
CN114588159A (zh) * 2020-12-07 2022-06-07 成都傲科新技术有限责任公司 一种治疗猫冠状病毒感染的化合物及其应用
CN114634529A (zh) * 2020-12-15 2022-06-17 中国科学院大连化学物理研究所 一种氟代瑞德西韦及其合成方法
US12558364B2 (en) 2021-01-20 2026-02-24 Regents Of The University Of Minnesota Next generation remdesivir antivirals
WO2022166581A1 (zh) * 2021-02-07 2022-08-11 石家庄迪斯凯威医药科技有限公司 一种核苷酸衍生物及其药物组合物和用途
US20240166680A1 (en) * 2021-04-15 2024-05-23 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Nucleoside analog and use thereof
EP4323361A1 (en) * 2021-04-16 2024-02-21 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
CN118591377A (zh) 2022-01-26 2024-09-03 加利福尼亚大学董事会 抗病毒前药、中效和长效制剂和方法
IL315102A (en) 2022-03-02 2024-10-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
PE20250419A1 (es) * 2022-03-03 2025-02-14 Gilead Sciences Inc Compuestos antivirales y metodos de elaboracion y uso de los mismos
CN114573590B (zh) * 2022-03-18 2023-11-14 苏州旺山旺水生物医药有限公司 一种四异丁酰基核苷类似物的制备方法及用途
CN116891474A (zh) * 2022-03-31 2023-10-17 苏州旺山旺水生物医药有限公司 一种单异丁酰基核苷类似物的制备方法
WO2024002112A1 (zh) * 2022-06-28 2024-01-04 苏州旺山旺水生物医药股份有限公司 一种治疗猫冠状或杯状病毒感染的方法
CN115894498A (zh) * 2022-10-01 2023-04-04 海化生命(厦门)科技有限公司 一种潜在抗病毒药物中间体bl及其合成方法
CN120152976A (zh) * 2022-10-23 2025-06-13 上海柯君医药科技有限公司 抗冠状病毒化合物及其组合物和用途
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
US20250090537A1 (en) * 2023-08-31 2025-03-20 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
CN117509571B (zh) * 2023-11-01 2025-12-05 乐威医药（江苏）股份有限公司 一种连续化制备叠氮化碘的方法及其应用
CN118304315B (zh) * 2024-04-12 2025-03-25 深圳安泰维生物医药有限公司 一种核苷类化合物在制备抗呼吸道合胞病毒感染相关产品上的用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120070415A1 (en) * 2010-09-22 2012-03-22 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
JP2013535453A (ja) * 2010-07-22 2013-09-12 ギリード・サイエンシズ・インコーポレーテッド パラミクソウイルス科ウイルス感染症を治療するための方法及び化合物
JP2016536288A (ja) * 2013-10-11 2016-11-24 アリオス バイオファーマ インク． 置換ヌクレオシド、置換ヌクレオチドおよびその類似体
WO2017049060A1 (en) * 2015-09-16 2017-03-23 Gilead Sciences, Inc. Methods for treating arenaviridae and coronaviridae virus infections
JP2017519780A (ja) * 2014-06-24 2017-07-20 アリオス バイオファーマ インク． 置換ヌクレオシド、ヌクレオチドおよびその類似体
JP2017519784A (ja) * 2014-06-24 2017-07-20 アリオス バイオファーマ インク． 置換ヌクレオシド、ヌクレオチドおよびその類似体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
WO2002057425A2 (en) 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2005020884A2 (en) 2003-05-14 2005-03-10 Idenix (Cayman) Limited Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
ES2398684T3 (es) * 2008-04-23 2013-03-21 Gilead Sciences, Inc. Análogos de carbanucleósido para el tratamiento antiviral
AU2013216595B2 (en) * 2008-04-23 2016-07-28 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
EP2313102A2 (en) * 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
PE20120995A1 (es) * 2009-09-21 2012-08-01 Gilead Sciences Inc Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
BR112013005872A2 (pt) 2010-09-22 2019-09-24 Alios Biopharma Inc compostos, composição farmacêutica e respectivos usos
AU2011349278C1 (en) * 2010-12-22 2017-01-19 Alios Biopharma, Inc. Cyclic nucleotide analogs
EP2794630A4 (en) * 2011-12-22 2015-04-01 Alios Biopharma Inc SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
TWI767201B (zh) 2014-10-29 2022-06-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
MA41213A (fr) * 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
CR20200126A (es) * 2017-09-18 2020-07-11 Janssen Biopharma Inc Nucleósidos sustituidos, nucleótidos y análogos de estos

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013535453A (ja) * 2010-07-22 2013-09-12 ギリード・サイエンシズ・インコーポレーテッド パラミクソウイルス科ウイルス感染症を治療するための方法及び化合物
US20120070415A1 (en) * 2010-09-22 2012-03-22 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
JP2016536288A (ja) * 2013-10-11 2016-11-24 アリオス バイオファーマ インク． 置換ヌクレオシド、置換ヌクレオチドおよびその類似体
JP2017519780A (ja) * 2014-06-24 2017-07-20 アリオス バイオファーマ インク． 置換ヌクレオシド、ヌクレオチドおよびその類似体
JP2017519784A (ja) * 2014-06-24 2017-07-20 アリオス バイオファーマ インク． 置換ヌクレオシド、ヌクレオチドおよびその類似体
WO2017049060A1 (en) * 2015-09-16 2017-03-23 Gilead Sciences, Inc. Methods for treating arenaviridae and coronaviridae virus infections

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023540225A (ja) * 2020-08-27 2023-09-22 ギリアード サイエンシーズ， インコーポレイテッド ウイルス感染症の治療のための化合物及び方法
JP7560659B2 (ja) 2020-08-27 2024-10-02 ギリアード サイエンシーズ， インコーポレイテッド ウイルス感染症の治療のための化合物及び方法
JP2024178294A (ja) * 2020-08-27 2024-12-24 ギリアード サイエンシーズ， インコーポレイテッド ウイルス感染症の治療のための化合物及び方法
JP2023541960A (ja) * 2020-09-17 2023-10-04 メレティオス セラピューティクス ウイルス感染を治療するための化合物
KR20230127294A (ko) * 2020-12-30 2023-08-31 서던 유니버시티 오브 사이언스 앤드 테크놀로지 코로나 바이러스 감염을 치료하기 위한 방법 및 변형된뉴클레오사이드
JP2024503755A (ja) * 2020-12-30 2024-01-26 サウザン・ユニバーシティ・オブ・サイエンス・アンド・テクノロジー ウイルス感染症治療用ヌクレオシド系化合物及びその用途
KR102918401B1 (ko) 2020-12-30 2026-01-26 서던 유니버시티 오브 사이언스 앤드 테크놀로지 코로나 바이러스 감염을 치료하기 위한 방법 및 변형된 뉴클레오사이드
KR20230170745A (ko) * 2021-04-16 2023-12-19 길리애드 사이언시즈, 인코포레이티드 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법
JP2024512771A (ja) * 2021-04-16 2024-03-19 ギリアード サイエンシーズ， インコーポレイテッド アミドを使用してカルバヌクレオシドを調製する方法
JP7688152B2 (ja) 2021-04-16 2025-06-03 ギリアード サイエンシーズ， インコーポレイテッド アミドを使用してカルバヌクレオシドを調製する方法
KR102923359B1 (ko) 2021-04-16 2026-02-05 길리애드 사이언시즈, 인코포레이티드 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법
WO2023022216A1 (ja) * 2021-08-20 2023-02-23 塩野義製薬株式会社 ウイルス増殖抑制作用を有するヌクレオシド誘導体及びそれらのプロドラッグ

Also Published As

Publication number Publication date
KR20200098483A (ko) 2020-08-20
IL273341A (en) 2020-05-31
SG11202002295QA (en) 2020-04-29
EP3684782A1 (en) 2020-07-29
ECSP20022130A (es) 2020-07-31
US20210395288A1 (en) 2021-12-23
EA202090775A1 (ru) 2020-07-06
BR112020005177A2 (pt) 2020-09-15
CN111542531B (zh) 2024-07-19
MX2020002925A (es) 2020-10-05
CR20200126A (es) 2020-07-11
AU2018332540A1 (en) 2020-04-30
WO2019053696A1 (en) 2019-03-21
KR102696517B1 (ko) 2024-08-21
CA3075950A1 (en) 2019-03-21
CL2020000685A1 (es) 2020-10-23
US11149049B2 (en) 2021-10-19
US11773126B2 (en) 2023-10-03
US20200277321A1 (en) 2020-09-03
CN111542531A (zh) 2020-08-14
AU2018332540B2 (en) 2023-10-05
PH12020550114A1 (en) 2020-12-07
MA50172A (fr) 2021-04-07

Similar Documents

Publication Publication Date Title
US11773126B2 (en) Substituted nucleosides, nucleotides and analogs thereof
CA2927010C (en) Substituted nucleosides, nucleotides and analogs thereof
EP3980400B1 (en) Peptidomimetics for the treatment of coronavirus and picornavirus infections
AU2011349278B2 (en) Cyclic nucleotide analogs
ES2278009T3 (es) Derivados de nucleosidos como inhibidores de la arn polimerasa virica dependiente de arn.
TW201811339A (zh) 經取代之核苷、核苷酸及其類似物
ES2716158T3 (es) 2'-spiro-nucleótidos para el tratamiento de hepatitis C
ES2744587T3 (es) Análogos de N-nucleósido de pirimidina 1-sustituidos para un tratamiento antiviral
TW201625658A (zh) 經取代之核苷、核苷酸及其類似物
AU2018203695A1 (en) Substituted nucleosides, nucleotides and analogs thereof
CN107250146A (zh) 取代的核苷、核苷酸及其类似物
WO2014070771A1 (en) Pyrimidine nucleotides and their monophosphate prodrugs for treatment of viral infections and cancer
CA2952966A1 (en) Substituted nucleosides, nucleotides and analogs thereof
IL217228A (en) Compounds of Type 2'-Deoxy-2'-Fluoro-2'-c-Methyluridine Nucleoside Phosphoramide Compounds
BR112020005177B1 (pt) Compostos análogos de nucleotídeos substituídos, seus usos, e composição farmacêutica
EA042416B1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
OA19518A (en) Substituted nucleosides, nucleotides and analogs thereof.
BR112021010236A2 (pt) Análogos de ciclobutil nucleosídeos como antivirais
KR20260016917A (ko) 항바이러스제로서의 4'-치환 뉴클레오사이드 및 뉴클레오타이드

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210917

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230928

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231006

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231110

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250411